⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005517 | 0.65 | — | — | |
| SCHEMBL16782327 | 0.65 | — | — | |
| SCHEMBL452537 | 0.65 | — | — | |
| SCHEMBL27519 | 0.62 | — | — | |
| SCHEMBL88632 | 0.58 | — | — | |
| SCHEMBL14437989 | 0.58 | ELANE (0.36) | — | |
| SCHEMBL8284736 | 0.58 | LMNA (0.34) | — | |
| SCHEMBL275756 | 0.58 | MAPT (0.41) | — | |
| SCHEMBL207972 | 0.58 | — | — | |
| SCHEMBL89836 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | JIANGNAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | claimed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | claimed |
| EP-3816160-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | Reborna Biosciences, Inc. (JP) | 2021-05-05 | — | — | EP | claimed |
| US-20210046027-A1 | Fatty Acid Synthase Inhibitor and Application Thereof | JIANGNAN UNIVERSITY (CN) | 2021-02-18 | — | — | US | claimed |
| WO-2020248327-A1 | FATTY ACID SYNTHASE INHIBITOR AND USE THEREOF | 江南大学 | 2020-12-17 | — | — | WO | claimed |
| US-10118919-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2018-11-06 | — | — | US | claimed |
| US-20180022738-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | claimed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | claimed |
| EP-3010916-B1 | 1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-9718785-B2 | 1,3-Disubstituted cyclopentane derivatives | MERCK PATENT GMBH (DE) | 2017-08-01 | — | — | US | claimed |
| WO-2007139955-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | claimed |
| WO-2007139968-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | claimed |
| EP-1817295-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2007-08-15 | — | — | EP | claimed |
| US-20070123523-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-05-31 | — | — | US | claimed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | claimed |
| WO-2006055760-A9 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | claimed |
| WO-2006055760-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | claimed |
| WO-2004112709-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-12-29 | — | — | WO | claimed |